Relmada Therapeutics, Inc.

As of June 30, 2026, Relmada Therapeutics Inc carries a market capitalization of 645.35M, placing it among publicly traded companies globally. Its enterprise value stands at 454.77M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Relmada Therapeutics Inc's next confirmed earnings release is scheduled for November 5, 2026.

As of June 30, 2026, Relmada Therapeutics Inc has 106.67M shares outstanding.

These figures are as of June 30, 2026.

As of June 30, 2026, Relmada Therapeutics Inc maintains a current ratio of 29.52, meaning it holds 29.5x the short-term assets needed to cover near-term liabilities.

Over the twelve months ended June 30, 2026, Relmada Therapeutics Inc posted a negative return on equity (ROE) of -55.66, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -51.57, reflecting losses generated across the asset base. The company generates approximately - - in revenue per employee across its workforce of 17.00, a quick read on workforce productivity versus industry peers.

As of the close on October 22, 2026, Relmada Therapeutics Inc's stock has gained approximately 61.33% over the past 52 weeks. The 50-day moving average sits at 3.50, while the 200-day moving average is 4.65.

Over the twelve months ended June 30, 2026, Relmada Therapeutics Inc generated - - in revenue and converted that into -54.20M in net income, yielding earnings per share of -0.72. EBITDA reached -57.01M, while operating income came in at -57.01M.

These figures are as of June 30, 2026. Total book value stands at 180.80M, with working capital of 185.23M providing operational flexibility.

Relmada Therapeutics Inc produced -40.26M in operating cash flow over the twelve months ended June 30, 2026.

These figures cover the twelve months ended June 30, 2026. Free cash flow yield is negative at -8.86: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -33.07, meaning Relmada Therapeutics Inc raised more capital through share issuance and new debt than it returned via dividends and buybacks.

Relmada Therapeutics Inc's most recent stock split took place on September 30, 2019 with a 4:1 split ratio.

As of June 30, 2026, Relmada Therapeutics Inc has an Altman Z-Score of 30.90, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.